Switch theme
Sign up to access all valuation multiples
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.
2005
n/a
LTM Revenue n/a
LTM EBITDA n/a
$394M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hyundai Bioscience has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Hyundai Bioscience achieved revenue of $10.3M and an EBITDA of -$2.7M.
Hyundai Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hyundai Bioscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.5M | $10.3M | XXX | XXX | XXX |
| Gross Profit | $1.8M | $3.4M | XXX | XXX | XXX |
| Gross Margin | 28% | 33% | XXX | XXX | XXX |
| EBITDA | -$8.7M | -$2.7M | XXX | XXX | XXX |
| EBITDA Margin | -134% | -26% | XXX | XXX | XXX |
| Net Profit | -$10.8M | -$9.9M | XXX | XXX | XXX |
| Net Margin | -167% | -96% | XXX | XXX | XXX |
| Net Debt | $2.2M | $2.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hyundai Bioscience's stock price is KRW 11560 (or $8).
Hyundai Bioscience has current market cap of KRW 555B (or $378M), and EV of KRW 578B (or $394M).
See Hyundai Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $394M | $378M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hyundai Bioscience has market cap of $378M and EV of $394M.
Hyundai Bioscience's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Hyundai Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hyundai Bioscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $394M | XXX | XXX | XXX |
| EV/Revenue | 38.4x | XXX | XXX | XXX |
| EV/EBITDA | -145.1x | XXX | XXX | XXX |
| P/E | -80.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 6607.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHyundai Bioscience's NTM/LTM revenue growth is n/a
Hyundai Bioscience's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Hyundai Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hyundai Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hyundai Bioscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 59% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -69% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 74% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hyundai Bioscience acquired XXX companies to date.
Last acquisition by Hyundai Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Hyundai Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hyundai Bioscience founded? | Hyundai Bioscience was founded in 2005. |
| Where is Hyundai Bioscience headquartered? | Hyundai Bioscience is headquartered in South Korea. |
| Who is the CEO of Hyundai Bioscience? | Hyundai Bioscience's CEO is Mr. Sang-gi Oh. |
| Is Hyundai Bioscience publicy listed? | Yes, Hyundai Bioscience is a public company listed on KRX. |
| What is the stock symbol of Hyundai Bioscience? | Hyundai Bioscience trades under 048410 ticker. |
| When did Hyundai Bioscience go public? | Hyundai Bioscience went public in 2002. |
| Who are competitors of Hyundai Bioscience? | Similar companies to Hyundai Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Hyundai Bioscience? | Hyundai Bioscience's current market cap is $378M |
| What is the current revenue growth of Hyundai Bioscience? | Hyundai Bioscience revenue growth between 2023 and 2024 was 59%. |
| Is Hyundai Bioscience profitable? | Yes, Hyundai Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
